<DOC>
	<DOC>NCT01812746</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).</brief_summary>
	<brief_title>A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the prostate Metastatic disease progressing despite castrate levels of testosterone Prostate cancer progression documented by PSA Surgically or medically castrated, with testosterone levels of &lt; 50 ng/dL Previous antiandrogen therapy and progression after withdrawal ECOG performance status of 0 to 1 Adequate organ function Prior radiation therapy allowed to &lt; 25% of the bone marrow Prior hormonal therapy is allowed Patient compliance and geographic proximity that allow adequate followup. Patients with reproductive potential must use contraceptive methods Signed informed consent from patient Active infection Any chronic medical condition requiring a high doses of corticosteroid Pathological finding consistent with small cell carcinoma of the prostate Brain metastasis Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC Radiation therapy for treatment of the primary tumor within 6 weeks Radionuclide therapy for treatment of metastatic CRPC Prior systemic treatment with an azole drug Prior flutamide treatment within 4 weeks Prior bicalutamide or nilutamide within 6 weeks Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia Administration of an investigational therapeutic within 2 weeks Second primary malignancy Presence of clinically detectable thirdspace fluid collections History of severe hypersensitivity reaction to polysorbate 80 Peripheral neuropathy at study entry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>